AAAAAA

   
Results: 1-25 |
Results: 25
LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS
Authors: KROGER N KRUGER WH GIESEKING F JAENICKE F SCHULTZE W FUSS H MOBUS V KONIGSMANN M BERDEL WE SCHAFERECKERT K WANDT H METZNER B ILLIGER HJ FRICKHOFEN N WULF G WORMANN B KOLBE K HOSSFELD DK MAAS H JONAT W ZANDER AR
Citation: N. Kroger et al., LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS, European journal of cancer, 34, 1998, pp. 92-92
FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS
Authors: BOKEMEYER C HARSTRICK A BEYER J METZNER B RUTHER U HARTMANN JT HOLSTEIN K DERIGS HG DEWIT R CASPER J SCHOFFSKI P KUHRER I ILLIGER HJ KEMPF B REICHLE A FOLLER A HOSSFELD DK FISCHER JT BERDEL W GERHARTZ H KIRCHNER H PFLUGER K OSTERMANN H KANZ L SCHMOLL HJ
Citation: C. Bokemeyer et al., FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Onkologie, 21, 1998, pp. 23-25
CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/
Authors: KRUGER WH KROGER N KONIGMANN M BERDEL WE FUSS H SCHULTZE W GIESEKING F SCHAFERECKART K MOBUS V FRICKHOFEN N WANDT H ILLIGER HJ METZNER B KOLBE K WORMANN B TRUMPER L HUBER C MAASS H JONAT W ZANDER AR
Citation: Wh. Kruger et al., CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/, Bone marrow transplantation, 22, 1998, pp. 31-31
LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER
Authors: KRUGER WH KROGER N KOLBE K HUBER C GIESEKING F JANICKE F KONIGSMANN M BERDEL WE KERSCHGENS C MAYR AC SCHAFERECKERT K WANDT H SCHULTZE W FUSS H METZNER B ILLIGER HJ FRICKHOFEN N MOBUS V HOSSFELD DK JONAT W ZANDER AR
Citation: Wh. Kruger et al., LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER, Bone marrow transplantation, 21, 1998, pp. 221-221
THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS
Authors: BOKEMEYER C HARSTRICK A BEYER J METZNER B RUTHER U HARTMANN JT HOLSTEIN K DERIGS HG DEWIT R CASPER J SCHOFFSKI P KUHRER I ILLIGER HJ KEMPF B REICHLE A FOLLER A HOSSFELD DK FISCHER JT BERDEL WE GERHARTZ HH KIRCHNER H PFLUGER KH OSTERMANN H KANZ L SCHMOLL HJ
Citation: C. Bokemeyer et al., THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Seminars in oncology, 25(2), 1998, pp. 24-32
HIGH-DOSE CHEMOTHERAPY WITH BUSULFAN, CYCLOPHOSPHAMIDE, AND ETOPOSIDEAS CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN FIRST COMPLETE REMISSION
Authors: ZANDER AR BERGER C KROGER N STOCKSCHLADER M KRUGER W HORSTMANN M GRIMM J ZELLER W KABISCH H ERTTMANN R SCHONROCK P KUSE R BRAUMANN D ILLIGER HJ FIEDLER W DEWITT M HOSSFELD KD WEH HJ
Citation: Ar. Zander et al., HIGH-DOSE CHEMOTHERAPY WITH BUSULFAN, CYCLOPHOSPHAMIDE, AND ETOPOSIDEAS CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN FIRST COMPLETE REMISSION, Clinical cancer research, 3(12), 1997, pp. 2671-2675
A PHASE-III TRIAL COMPARING VOROZOLE (RIVIZOR(TM)) VERSUS AMINOGLUTETHIMIDE IN THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER
Authors: BENGTSSON NO FOCAN C GUDGEON A ILLIGER HJ KHAYAT D MURRAY R NORTIER JWR WAXMAN J ZIELINSKI C
Citation: No. Bengtsson et al., A PHASE-III TRIAL COMPARING VOROZOLE (RIVIZOR(TM)) VERSUS AMINOGLUTETHIMIDE IN THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER, European journal of cancer, 33, 1997, pp. 656-656
ACTIVITY AND TOLERABILITY OF GEMCITABINE PLUS CISPLATIN IN ADVANCED METASTATIC PANCREATIC-CARCINOMA
Authors: HEINEMANN V WILKE H POSSINGER K MERGENTHALER K CLEMENS M KONIG HJ ILLIGER HJ LACKHOFF A BLATTER J SCHALLHORN A FINK U
Citation: V. Heinemann et al., ACTIVITY AND TOLERABILITY OF GEMCITABINE PLUS CISPLATIN IN ADVANCED METASTATIC PANCREATIC-CARCINOMA, European journal of cancer, 33, 1997, pp. 1240-1240
ESMO CERTIFICATION AND ESMO-MORA - A CONT RIBUTION TO QUALITY PROTECTION IN MEDICAL TUMOR-THERAPY
Authors: ILLIGER HJ
Citation: Hj. Illiger, ESMO CERTIFICATION AND ESMO-MORA - A CONT RIBUTION TO QUALITY PROTECTION IN MEDICAL TUMOR-THERAPY, Onkologie, 20(3), 1997, pp. 244-246
GLUCOCORTICOIDS IN HEMATOLOGY AND MEDICAL -ONCOLOGY
Authors: ILLIGER HJ
Citation: Hj. Illiger, GLUCOCORTICOIDS IN HEMATOLOGY AND MEDICAL -ONCOLOGY, Der Internist, 38(5), 1997, pp. 485-488
THE MONOCLONAL-ANTIBODY 17-1A (PANOREX) - A NEW APPROACH TO ADJUVANT THERAPY OF COLON-CANCER
Authors: ILLIGER HJ
Citation: Hj. Illiger, THE MONOCLONAL-ANTIBODY 17-1A (PANOREX) - A NEW APPROACH TO ADJUVANT THERAPY OF COLON-CANCER, Der Internist, 38(10), 1997, pp. 1001-1006
DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD STEM-CELL HARVESTS OFPATIENTS WITH PROGRESSIVE METASTATIC MALIGNANT-MELANOMA
Authors: PROBSTKEPPER M SCHRADER A BUER J GROSSE J VOLKENANDT M ILLIGER HJ METZNER B KADAR J DUENSING S HERTENSTEIN B GANSER A ATZPODIEN J
Citation: M. Probstkepper et al., DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD STEM-CELL HARVESTS OFPATIENTS WITH PROGRESSIVE METASTATIC MALIGNANT-MELANOMA, British Journal of Haematology, 98(2), 1997, pp. 488-490
ASHAP SALVAGE THERAPY FOR RECURRENT AND REFRACTORY HODGKINS-DISEASE (HD) AND NON-HODGKINS-LYMPHOMA (NHL)
Authors: HANEL M HOFFKNECHT MM PETERS SO FIEDLER F HANEL A KRUGER WH ZELLER W BRAUMANN D ILLIGER HJ METZNER B SCHUBERT JC SCHMITZ N WEH HJ KROGER N ZANDER AR
Citation: M. Hanel et al., ASHAP SALVAGE THERAPY FOR RECURRENT AND REFRACTORY HODGKINS-DISEASE (HD) AND NON-HODGKINS-LYMPHOMA (NHL), Blood, 90(10), 1997, pp. 4559-4559
RANDOMIZED COMPARISON OF COPP ABVD VS. DOSE-ESCALATED AND TIME-ESCALATED COPP/ABVD WITH GM-CSF SUPPORT FOR ADVANCED HODGKINS-DISEASE/
Authors: GERHARTZ HH SCHWENKE H BAZARBASHI S THIEL E BLAU W HUHN D HEIMPEL H BROWN P SCHLIEMOK G ILLIGER HJ WALTHER J WILMANNS W CHARISSE G FARBER L HAUS U
Citation: Hh. Gerhartz et al., RANDOMIZED COMPARISON OF COPP ABVD VS. DOSE-ESCALATED AND TIME-ESCALATED COPP/ABVD WITH GM-CSF SUPPORT FOR ADVANCED HODGKINS-DISEASE/, Blood, 90(10), 1997, pp. 1731-1731
INTEGRATION OF G-CSF IN THE PROPHYLAXIS A ND TREATMENT OF FEBRILE NEUTROPENIA
Authors: SIEGMUND R ILLIGER HJ
Citation: R. Siegmund et Hj. Illiger, INTEGRATION OF G-CSF IN THE PROPHYLAXIS A ND TREATMENT OF FEBRILE NEUTROPENIA, Medizinische Klinik, 91(2), 1996, pp. 82-88
EPIRUBICIN AND IFOSFAMIDE IN METASTATIC BREAST-CANCER
Authors: BECHER R KLOKE O HAYUNGS J HARTWICH G BARTELS H SZANTO J WOLF E ILLIGER HJ HALABI S RIECHE K HERING KG OHL S DEDYCKER R HUHN R FISCHEDICK AR HOFELER H PIELKEN HJ HAWIG I HIRCHE H SEEBER S
Citation: R. Becher et al., EPIRUBICIN AND IFOSFAMIDE IN METASTATIC BREAST-CANCER, Seminars in oncology, 23(3), 1996, pp. 28-33
MULTIINSTITUTIONAL HOME-THERAPY TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-2 AND INTERFERON ALFA-2 IN PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA
Authors: ATZPODIEN J HANNINEN EL KIRCHNER H BODENSTEIN H PFREUNDSCHUH M REBMANN U METZNER B ILLIGER HJ JAKSE G NIESEL T SCHOLZ HJ WILHELM S PIELMEIER T ZAKRZEWSKI G BLUM G BEIER J MULLER GW DUENSING S ANTON P ALLHOFF E JONAS U POLIWODA H
Citation: J. Atzpodien et al., MULTIINSTITUTIONAL HOME-THERAPY TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-2 AND INTERFERON ALFA-2 IN PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA, Journal of clinical oncology, 13(2), 1995, pp. 497-501
REPORT ON THE 10TH ANNIVERSARY CONFERENCE OF THE WILSEDE-SCHOOL, OCTOBER-1994
Authors: BOKEMEYER C ILLIGER HJ
Citation: C. Bokemeyer et Hj. Illiger, REPORT ON THE 10TH ANNIVERSARY CONFERENCE OF THE WILSEDE-SCHOOL, OCTOBER-1994, Onkologie, 18(1), 1995, pp. 92-92
WEEKLY THERAPY WITH FOLINIC ACID (FA) AND HIGH-DOSE 5-FLUOROURACIL (5-FU) 24-HOUR INFUSION IN PRETREATED PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA - A MULTICENTER STUDY BY THE ASSOCIATION OF MEDICAL ONCOLOGY OF THE GERMAN-CANCER-SOCIETY (AIO)
Authors: WEH HJ WILKE HJ DIERLAMM J KLAASSEN U SIEGMUND R ILLIGER HJ SCHALHORN A KREUSER ED HILGENFELD U STEINKE B WEBER W BURKHARD O ZOLLER A PFITZNER J SUBERT R KRIEBEL R HOSSFELD DK
Citation: Hj. Weh et al., WEEKLY THERAPY WITH FOLINIC ACID (FA) AND HIGH-DOSE 5-FLUOROURACIL (5-FU) 24-HOUR INFUSION IN PRETREATED PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA - A MULTICENTER STUDY BY THE ASSOCIATION OF MEDICAL ONCOLOGY OF THE GERMAN-CANCER-SOCIETY (AIO), Annals of oncology, 5(3), 1994, pp. 233-237
ONCOLOGICAL TREATMENT - AMBULATORY OR INP ATIENT
Authors: ILLIGER HJ
Citation: Hj. Illiger, ONCOLOGICAL TREATMENT - AMBULATORY OR INP ATIENT, Medizinische Klinik, 89(1), 1994, pp. 39-40
ROLE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF GERM-CELL TUMORS
Authors: BOKEMEYER C HARSTRICK A RUTHER U METZNER B ILLIGER HJ CLEMM C SIEGERT W LINK H OSTERMANN H SCHMOLL HJ
Citation: C. Bokemeyer et al., ROLE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF GERM-CELL TUMORS, Seminars in oncology, 21(6), 1994, pp. 57-63
A PHASE I II STUDY OF A STEPWISE DOSE-ESCALATED REGIMEN OF CISPLATIN,ETOPOSIDE AND IFOSFAMIDE PLUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) IN PATIENTS WITH ADVANCED GERM-CELL TUMORS/
Authors: BOKEMEYER C SCHMOLL HJ HARSTRICK A ILLIGER HJ METZNER B RATH U HOHNLOSER J CLEMM C BERDEL W SIEGERT W RUTHER U OSTERMANN H KNEBA M HARTLAPP JH SCHRODER M POLIWODA H
Citation: C. Bokemeyer et al., A PHASE I II STUDY OF A STEPWISE DOSE-ESCALATED REGIMEN OF CISPLATIN,ETOPOSIDE AND IFOSFAMIDE PLUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) IN PATIENTS WITH ADVANCED GERM-CELL TUMORS/, European journal of cancer, 29A(16), 1993, pp. 2225-2231
COMPARISON OF 5 VS 10 MU-G KG PER DAY OF GM-CSF FOLLOWING DOSE-INTENSIFIED CHEMOTHERAPY WITH CISPLATIN, ETOPOSIDE, AND IFOSFAMIDE IN PATIENTS WITH ADVANCED TESTICULAR CANCER/
Authors: BOKEMEYER C SCHMOLL HJ METZNER B BEYER J ILLIGER HJ KNEBA M OSTERMANN H KYNAST B RATH U POLIWODA H
Citation: C. Bokemeyer et al., COMPARISON OF 5 VS 10 MU-G KG PER DAY OF GM-CSF FOLLOWING DOSE-INTENSIFIED CHEMOTHERAPY WITH CISPLATIN, ETOPOSIDE, AND IFOSFAMIDE IN PATIENTS WITH ADVANCED TESTICULAR CANCER/, Annals of hematology, 67(2), 1993, pp. 75-79
TOPICALLY APPLIED MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH SKIN-METASTASIZED BREAST-CANCER - A PHASE-II STUDY
Authors: UNGER C HERRMANN R BERDEL WE KLEEBERG UR GATZEMEIER U ILLIGER HJ WANDER HE WESTERHAUSEN M BECHER R BREMER K RIECHE K ESSERS U QUEISSER W HEIDEMANN E FIEBIG HH POSSINGER K JOURDAINMADL B HEIM ME EDLER L
Citation: C. Unger et al., TOPICALLY APPLIED MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH SKIN-METASTASIZED BREAST-CANCER - A PHASE-II STUDY, Onkologie, 16(3), 1993, pp. 170-173
ADRIAMYCIN, CISPLATINUM, ARA-C AND METHYLPREDNISOLONE (ASHAP) COMBINATION CHEMOTHERAPY IN RELAPSED AND REFRACTORY LYMPHOMA AND NON-HODGKINSDISEASE
Authors: PETERSL SO SCHMITZ N METZNER B ILLIGER HJ SCHUBERT JC BRAUMANN D DORKEN B HIRSCHMANN WD KOPPLER H HAVEMANN K KRUGER W ZELLERL W WEHL HJ HOSSFELDL DK ZANDER AR
Citation: So. Petersl et al., ADRIAMYCIN, CISPLATINUM, ARA-C AND METHYLPREDNISOLONE (ASHAP) COMBINATION CHEMOTHERAPY IN RELAPSED AND REFRACTORY LYMPHOMA AND NON-HODGKINSDISEASE, Blood, 82(10), 1993, pp. 10000574-10000574
Risultati: 1-25 |